Related Experiment Video
Updated: May 18, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Future bronchodilator therapy: a bitter pill to swallow?
Summary
Novel bitter taste receptors (TAS2Rs) show promise as a new target for asthma therapy, offering an alternative to beta-agonists. Research is exploring TAS2R pathways for effective bronchodilation, potentially leading to better asthma treatments.
Area of Science:
- Pharmacology and Respiratory Medicine
- Investigating novel therapeutic targets for respiratory diseases
- Exploring the role of bitter taste receptors in airway function
Background:
- Current asthma therapies rely on beta-agonists, which can lead to desensitization and reduced efficacy with chronic use.
- Previous attempts at alternative bronchodilators, including K(ATP) channel agonists and cGMP activators, faced challenges like limited clinical success or side effects.
- The limitations of existing treatments highlight the need for novel therapeutic strategies in asthma management.
Discussion:
- Recent studies identify bitter taste receptor (TAS2R) signaling as a novel pathway for bronchodilation.
- These findings offer new insights into how TAS2Rs mediate airway smooth muscle relaxation.
- The interaction between TAS2R signaling and beta-agonist desensitization is a critical area of investigation.
Key Insights:
- TAS2Rs represent a promising new target for bronchodilator therapy in asthma.
- Understanding TAS2R signaling pathways is crucial for developing effective asthma medications.
- Bitter (TAS2R) agonists may offer a viable alternative or adjunct to traditional beta-agonist treatments.
Outlook:
- Further research is required to fully define TAS2R agonists and their therapeutic potential.
- Addressing remaining questions about TAS2R mechanisms and clinical efficacy is essential.
- The development of "bitter (better?)" therapies for asthma holds significant promise for improved patient outcomes.
Related Concept Videos
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...